{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6"},{"groupId":"OG001","value":"43.0"},{"groupId":"OG002","value":"53.7"},{"groupId":"OG003","value":"54.9"},{"groupId":"OG004","value":"57.2"},{"groupId":"OG005","value":"60.6"}]}],"title":"Responders with Remission (DAS<2.6)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7"},{"groupId":"OG001","value":"57.7"},{"groupId":"OG002","value":"67.0"},{"groupId":"OG003","value":"71.2"},{"groupId":"OG004","value":"70.6"},{"groupId":"OG005","value":"72.2"}]}],"title":"Responders with Low Disease Activity (DAS</= 3.2)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"516"},{"groupId":"OG001","value":"470"},{"groupId":"OG002","value":"430"},{"groupId":"OG003","value":"410"},{"groupId":"OG004","value":"381"},{"groupId":"OG005","value":"363"}],"units":"Participants"}],"description":"The disease activity score 28 (DAS28) is a combined index for measuring disease activity in rheumatic arthritis (RA) that includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The DAS28 scale ranges from 0 to 10, where lower scores represent less disease activity. Participants with DAS28 scores less than 2.6 were categorized as responders with remission and those with DAS 28 scores of 3.2 or less were categorized as responders with low disease activity (LDA). The percentage of participants classified as responders in each category was recorded over time.","groups":[{"description":"Participants with scores at 24 weeks post-baseline.","id":"OG000","title":"Week 24"},{"description":"Participants with scores at 48 weeks post-baseline.","id":"OG001","title":"Week 48"},{"description":"Participants with scores at 108 weeks post-baseline.","id":"OG002","title":"Week 108"},{"description":"Participants with scores at 156 weeks post-baseline.","id":"OG003","title":"Week 156"},{"description":"Participants with scores at 204 weeks post-baseline.","id":"OG004","title":"Week 204"},{"description":"Participants with scores at 264 weeks post-baseline.","id":"OG005","title":"Week 264"}],"paramType":"NUMBER","populationDescription":"All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.","reportingStatus":"POSTED","timeFrame":"through 264 Weeks","title":"Percentage of Participants Classified as Responders by Disease Activity Scores Over Time, Through 264 Weeks","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}